1. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen 
B.J. Werth, R. Jain, A. Hahn, L. Cummings, T. Weaver, A. Waalkes, D. Sengupta, S.J. Salipante, R.M. Rakita, S.M. Butler-Wu 
Clinical Microbiology and Infection 
Volume 24, Issue 4, Pages 429.e1-429.e5 (April 2018)
DOI: /j.cmi
Copyright © Terms and Conditions

2. Fig. 1
Population analysis profiles of initial blood isolate (S72982) and vancomycin intermediate derivative isolated from the urine (F34968), and hVISA control strain, Mu3.
Clinical Microbiology and Infection  , 429.e1-429.e5DOI: ( /j.cmi )
Copyright © Terms and Conditions